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Abstract: Background: Oncoproteomics is the study of proteins and their interactions in a cancer cell by proteomic tech-
nologies and has the potential to revolutionize clinical practice, including cancer diagnosis. Recent technological advances 
in the analysis of the human genome have opened the door to improving our primitive understanding of the gene expres-
sion patterns in cancer. The examination of the phenotypic and (epi) genetic changes in cutaneous melanoma has identi-
fied several genes deemed central to the development and progression of melanoma. 
Methods: A review of the literature was performed to determine the role of epigenetic modifications in human melanoma. 
The role of array-based high-throughput gene expression analysis in understanding the specific genes involved as well as 
the pathways and the comparative gene expression patterns of primary and metastatic melanoma. The development and 
clinical application of selective pharmacologic agents are also discussed. 
Results: We identified several articles that have extensively studied the role of epigenetics in melanoma, further elucidat-
ing the complex processes involved in gene regulation and expression. Other studies utilizing gene microarray analysis 
and other whole genome approaches reveal a wide array of genes and expression patterns in human melanoma. Several 
genes have been identified as potential prognostic markers of tumor progression and overall clinical outcome. 
Conclusions: High-throughput gene expression analysis has had a major impact in melanoma research. Several gene ex-
pression platforms have provided insight into the gene expression patterns in melanoma. Such data will provide founda-
tions for the future development of prognostic markers and improved targeted therapies for patients with melanoma. 
Keywords: Melanoma, genomics, epigenetics, miRNA, proteomics. 
INTRODUCTION 
  Melanoma is an aggressive and often fatal type of cancer 
that arises from transformed melanocytes. These long-lived 
pigment-producing cells typically colonize the basal epider-
mis during embryonal development. Melanoma, one of the 
most invasive and metastatic human cancers, is the major 
cause of death from skin cancer and is more likely to be 
reported and accurately diagnosed than non-melanoma skin 
cancers. According to the World Health Organization 
(WHO) statistics, the incidence of malignant melanoma in 
white populations generally increases with decreasing lati-
tude, with the highest recorded incidence occurring in Aus-
tralia where the annual rates are 10 and over 20 times the 
rates in Europe for women and men, respectively. Since the 
early 1970s, malignant melanoma incidence has increased 
significantly, for example an average of 4% every year in the 
United States [1]. In addition, melanoma is the fifth most 
common cancer for men and the sixth most common for 
women. The incidence of many common cancers is falling, 
but the incidence of melanoma continues to rise significantly 
at a rate faster than that of any of the 7 most common can-
cers. 
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  The tumor-node-metastasis (TNM) staging system for 
node negative melanoma is based on survival data from more 
than 27,000 stage I and II melanoma patients. These data 
identified primary tumor thickness (also known as Breslow 
depth), ulceration, and a mitotic rate higher than 1/mm
2 as 
factors associated with worse survival. For example, primary 
tumor thickness was a strong predictor of survival, and 92% 
of patients with node negative, T1 (of <1 mm thickness) 
melanoma primary tumors survived 10 years compared with 
only 50% of patients with node negative T4 (of >4 mm 
thickness) tumors. The new staging guidelines from the 
American Joint Committee on Cancer (AJCC) also identified 
primary tumor ulceration as an independent prognosticator of 
survival, and in a pooled meta-analysis of 3 large adjuvant 
interferon trials E1684, E1690, and E1694, primary tumor 
ulceration was associated with worse relapse-free survival 
(RFS, HR = 1.54) and overall survival (OS, HR = 1.73). 
Interestingly, post-hoc analysis of 2 large European trials, 
EORTC 18952 and EORTC 18991, also suggested that pa-
tients with ulcerated primary lesions, particularly those with 
no more than minimal nodal metastases, may benefit more 
from treatment with adjuvant interferon than patients with 
non-ulcerated primary lesions. In these patients, interferon 
substantially decreased the risk of relapse by 25%, the risk of 
developing distant metastasis by 31%, and the risk of death 
by 31% [2]. New Perspectives of “Omics” Applications in Melanoma Research  The Open Biochemistry Journal, 2011, Volume 5    61 
  Although the pathogenetic mechanisms underlying mela-
noma development are still largely unknown, several genes 
and metabolic pathways have been shown to carry molecular 
alterations in melanoma 
  The mitogen-activated protein kinases/extracellular sig-
nal–regulated kinase (MAPK-ERK) pathway (including the 
cascade of neuroblastoma RAS viral (v-ras) oncogene ho-
molog (NRAS) , v-raf murine sarcoma viral oncogene ho-
molog B1 (BRAF), mitogen-activated protein kinase 1/2 
(MEK1/2, also known as MAP2K1/2), and mitogen-
activated protein kinase 3/1  (ERK1/2, also known as 
MAPK3/1), which is involved in the control of cell growth, 
proliferation and migration, has been reported to play a ma-
jor role in both the development and progression of mela-
noma and seems to be implicated in rapid melanoma cell 
growth, enhanced cell survival, and resistance to apoptosis 
[3]. Therefore, existing evidence suggests that activating 
BRAF mutations induce cell proliferation and cell survival, 
which represent 2 biological events occurring in both mela-
nocytic expansion of nevi and malignant progression from 
superficial to invasive disease [4]. 
  In recent years, a common mechanism for the induction 
of cell senescence has been described: a progressive-
reduction in the length of telomeres (often in conjunction 
with overactivity of specific oncogenes such as v-myc mye-
locytomatosis viral oncogene homolog (avian) (MYC) and 
ataxia telangiectasia mutated (ATM) seems to exert DNA 
damage signaling with activation of the p16 cyclin-
dependent kinase inhibitor 2A (CDKN2A) pathway [5]. 
Nevertheless, cancers including melanomas cannot grow 
indefinitely without a mechanism to extend telomeres. The 
expression and activity of telomerase is indeed upregulated 
in melanoma progression. This evidence strongly suggests 
that both telomere length and p16
CDKN2A act in a common 
pathway leading to growth-arrest of nevi. In particular, the 
p16
CDKN2A protein acts as an inhibitor of melanocytic prolif-
eration by binding the cyclin-dependent kinase 4/6 (CDK4/6) 
and blocking phosphorylation of the RB protein, which leads 
to cell cycle arrest [6]. The dysfunction of the proteins in-
volved in the p16
CDKN2A pathway has been demonstrated to 
promote uncontrolled cell growth, which may increase the 
aggressiveness of transformed melanocytic cells [7]. 
 The  p14
CDKN2A protein exerts a tumor suppressor effect 
by inhibiting the oncogenic actions of the downstream 
Mdm2 p53- binding protein homolog (mouse) (MDM2), 
whose direct interaction with p53 blocks any p53-mediated 
activity and targets the p53 protein for rapid degradation. 
Impairment of the p14
CDKN2A-MDM2-p53 cascade, whose 
final effectors are the B-cell CLL/lymphoma 2 (Bcl-2)- asso-
ciated X proteins (Bax), has been implicated in defective 
apoptotic responses to genotoxic damage and thus to anti-
cancer agents (in most cases, melanoma cells present concur-
rent high expression levels of Bax/Bcl-2 proteins, which may 
contribute to further increasing their aggressiveness and 
refractoriness to therapy) [8]. 
  Currently, thanks to the use of “omics” technologies 
(genomics, epigenetics, proteomics, etc.), new potential 
biomarkers are raising and broadening the possibilities of 
application for a future improvement of specificity and selec-
tivity in prognosis and diagnosis at different stages of mela-
noma disease. This review tends to show latest knowledge 
uncovered in this field.  
GENOMICS 
  The invasive potential in skin melanoma strictly depends 
on the thickness of the primary tumor, since there is a pro-
gressive increase in invasive and metastatic potential with 
the thickness of the primary tumor. In addition, the growth 
pattern also reflects the invasive potential: vertical growth 
pattern (VGP) represents invasiveness, while radial growth 
pattern (RGP) is the reflection of non-invasive phenotype. 
Gene signatures associated with thin and thick primary tu-
mors or VGP versus RGP tumors characterize predominantly 
invasive potentials (corresponding to metastasis initiators) 
but may also contain signatures for lymphatic and vascular 
metastatic ability as well as signatures for lymphatic and 
vascular metastasis maintenance. A quick overview of the 
microarray studies on human skin melanoma revealed that 
they were performed on a very heterogenous patient cohort 
and pathological sample collections containing primary tu-
mors, cutaneous metastases, and lymphatic and in some 
instances visceral metastases. Only 1 study defined the cuta-
neous metastasis signature [9], while none were able to iden-
tify the lymphatic metastasis signature [10]. It is remarkable 
that these metastasis-signatures of human skin melanoma are 
predominated by downregulated genes and only by a much 
more limited list of upregulated genes [9]. 
  A meta-analysis of genome-wide association studies was 
found. Studies investigating cell lines or publishing associa-
tion studies focusing on a set of pre-selected genes were not 
included in the study. All together 2,475 transcripts were 
associated with melanoma metastasis (cutaneous or lym-
phatic). Of these, 350 genes were identified in more than 1 
study. Only 19 probe sets representing 17 genes were identi-
fied in 3 studies [10] and only cell division control protein 28 
(CDC28) was identified in 4 studies. Another potential 
marker, desmocollin 3 (DSC3) gene, is a cell adhesion mole-
cule involved in melanocyte-keratinocyte communication, 
suggesting the importance of this gene in the development of 
invasiveness and RGP/VGP transition in melanoma [11]. 
Early events in melanoma invasion and metastasis may in-
volve alterations in cell proliferation [12] where genes in-
volved in cell cycle regulation are important: cell division 
cycle 6 homolog (CDC6) and protein kinase regulatory 
subunit 2 (CDC28/CKS2) are 2 representative of those genes. 
It is remarkable that 2 probe sets of epidermal growth factor 
receptor (EGFR) can be found in this consensus signature. 
EGFR was considered to be an important regulator of the 
biology of melanocytes and melanoma; however, a few ex-
perimental or pathological studies were able to define its 
precise role in progression [13]. S100 calcium binding pro-
tein B (S100B) is a marker of melanoma, while S100 cal-
cium binding protein A (S100A) family members are more 
related to progression, mostly the downregulation of their 
expression [14]. Important factors in early phase of mela-
noma progression may also involve various nuclear proteins 
such as  
  H2A histone family, member V (H2AFV), the neuroblast 
differentiation-associated protein (AHNAK), or -catenin-
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melanoma progression is indicated by the presence of 
chemokine (C-X-C motif) ligand 14 (CXCL14) in the signa-
ture. The interconverted phenotype of melanoma is charac-
terized by cytokin expression involved in melanoma progres-
sion. The role of wingless-type MMTV integration site fam-
ily, member 5 A (WNT5A) in melanoma progression is well 
documented in the literature [15] similar to the anti-apoptotic 
protein B-cell CLL/lymphoma 2 (BCL2) [16]. Moreover, the 
integrin ligand opsin (OPN) was repeatedly shown to be 
involved in the motility signaling of melanoma cells [17], 
indicating its role in progression. 
  Mutations and aberrations can be identified through the 
use of a variety of biotechniques such as array comparative 
genomic hybridization (CGH) and fluorescent in situ hy-
bridization (FISH). Using FISH data, investigators evaluated 
melanocytic lesions, including 3 cohorts of unequivocal 
melanocytic nevi and melanomas of varying levels of atypia, 
and a fourth cohort of ambiguous melanocytic tumors. A 
discriminatory algorithm was established and validated and 
was found to correctly classify melanoma with 86.7% sensi-
tivity and 95.4% specificity [18]. Array CGH allows for the 
quantification of DNA copy number variations, including the 
detection of single copy deletions and duplications. This can 
be performed on paraffin-embedded specimens. In melano-
mas evaluated using CGH, 96% had multiple genetic aberra-
tions, while nevi had none with the exception of Spitz nevi 
where a single specific aberration characterized by a single 
11p gain was found. This correlates with v-Ha-ras Harvey rat 
sarcoma viral oncogene homolog (HRAS) activation and 
MAPK activation. Typical congenital nevi evaluated with 
array CGH have no aberrations, while melanomas arising in 
congenital nevi have genetic patterns similar to de novo 
cutaneous melanoma. Proliferative nodules have frequent 
numerical chromosomal aberrations that differ from those 
seen in melanoma [19]. In another study, BRAF or NRAS 
mutations were observed in 86% of Spitzoid melanomas and 
Spitzoid melanoma metastases, but in none of the Spitz nevi 
and atypical Spitz nevi evaluated [20]. Using array CGH and 
FISH, histologically and clinically normal appearing skin 
adjacent to acral melanoma was found to have genetic ampli-
fications in 84% at distances up to an average of 6.1 mm 
from visible melanoma in situ and 4.5 mm from invasive 
malignant melanoma [21]. 
  In a large expression study of human primary melano-
mas, it was found that 23 of 24 genes involved in DNA re-
pair have increased expression correlated with thickness, as 
did all the examined genes associated with cell cycle (8 
genes), protein folding (10 genes), chromatin remodeling (10 
genes), and heat shock protein activity (11 genes). In con-
trast, decreased expression with increasing thickness of pri-
mary melanoma was observed for all examined genes in-
volved in serine-type endopeptidase inhibitor activity (15 
genes), cell adhesion (15 genes), cell-cell signaling (8 
genes), and transcription factor activity (33 of the 36 genes 
examined) [22]. 
  Among the intrinsic properties of melanoma that may 
favor both ulceration and dissemination are proliferative 
activity of the tumor and overexpression of c-myc [23]. In a 
work of dendritic cell (DC) maturation in the sentinel lymph 
nodes (SLNs) draining melanoma, it was found that the 
maximum mature DC density in the SLNs correlated signifi-
cantly and inversely with ulceration of the primary mela-
noma (P = 0.0005) [24]. It is of interest to put this finding 
parallel to a more pronounced impact of pegylated inter-
feron-a2b (PEG-IFN) on recurrence-free survival in patients 
with ulcerated melanoma, as compared with patients with 
non-ulcerated melanoma [25]. 
  Genes identified in another validated and reproducible 
signature prognosticating metastases or death are mainly 
associated with DNA replication or DNA repair. In DNA 
replication, genes of 2 pathways are over-represented: repli-
cation origins firing (ROF) genes and the separation of sis-
ter-chromatids by securin [22, 26]. Melanomas with poor 
prognoses are characterized by a global overexpression of 
ROF-related genes. The minichromosome maintenance 
complex component 4/6 (MCM4/6) expression is strongly 
correlated with metastasis-free survival and overall survival 
[22]. Securin has 3 known activities: it blocks the sister-
chromatids separation in stabilising separase, it stimulates 
angiogenesis and, it decreases p53 transcription. Securin acts 
as an oncogene, and its expression is observed by immuno-
histochemical staining in the vertical growth phase but not in 
the radial growth phase of melanoma [27]. Table 1 shows a 
selection of candidate biomarkers from tissue microarrays 
that need confirmation from independent data sets and/or 
prospectively collected data sets preferentially from clinical 
trials. Table 2 summarizes a set of prognostic serum bio-
markers [28] . 
Table  1. Prognostic Cutaneous Melanoma Biomarkers   
Detected by Immunohistochemical Analysis of   
Tissue Microarrays 
Prognostic Tissue Biomarkers 
Cellular heat shock protein chaperone (HSP90) 
Regulator of G protein signaling 1 (RGS1) 
Osteopontin 
Epidermal growth factor receptor family member 3 (HER3) 
Inhibitor of growth family member 4 (ING4) 
Inhibitor of growth family member 3 (ING3) 
Nuclear receptor coactivator-3 (NCOA3) 
Minichromosome maintenance protein family member 4 (MCM4) 
Minichromosome maintenance protein family member 6 (MCM6) 
Table  2. Prognostic Serum Biomarkers of Cutaneous   
Melanoma 
Prognostic Serum Biomarkers 
Lactate dehydrogenase (LDH)* 
Calcium-binding protein S100B 
Melanoma-inhibiting activity (MIA) 
Tumor-associated antigen 90 immune complex (TA90IC) 
Mammalian chitinase-like proteins member YKL-40 
*Included in the AJCC staging system, and patients with distant metastases and 
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EPIGENETIC AND MICRO-RNA STUDIES 
  Recently, the epigenetic mechanisms involved most often 
in gene silencing in melanoma have come to the forefront of 
research, highlighting unique perspectives on the gene regu-
lation of melanoma, and how this relates to tumor suppres-
sion and metastatic potential. The hallmarks of epigenetic 
gene regulation are DNA methylation and histone modifica-
tions [29]. 
  DNA hypermethylation contributes to gene silencing by 
preventing the binding of activating transcription factors and 
by attracting repressor complexes that induce the formation 
of inactive chromatin structures. Currently, more than 50 
genes have been identified to be aberrantly hypermethylated 
during some phase of melanoma progression and metastasis 
[29]. A cytosine nucleotide next to a guanine nucleotide 
(CpG) island DNA hypermethylation seems to play a central 
role in melanoma progression and metastasis. A recent work 
reports that the methylation events involved in advanced-
stage melanoma was examined by extensively screening the 
methylation status of the promoter regions of 30 “cancer-
related” genes utilizing a sensitive and quantitative methyla-
tion-specific polymerase chain reaction (PCR)-based assay 
(Q-MSP), performed on 20 melanoma cell lines and 40 hu-
man melanoma samples [29]. The analysis of this large panel 
gave raise to identify 4 new genes: decoy receptor 1 (DcR1), 
decoy receptor 2 (DcR2), lysyl oxidase (LOX), and tropomy-
osin 1 (alpha) (TPM1) implicated as hypermethylated in 
human melanoma, with an overall methylation frequency of 
60%, 80%, 50%, and 10%, respectively [28]. Another gene 
stratifin (also known as 14-3-3) was first identified as an 
epithelial cell antigen (HME-1) exclusively expressed in 
human epithelia. Experimental data demonstrate that the 14-
3-3 gene is highly expressed in normal skin but undetect-
able in normal melanocytes and in most melanoma cells. We 
have found that the promoter CpG islands in the 14-3-3 
gene are heavily methylated in both normal melanocytes and 
most melanoma cells in a cell-lineage specific manner [29]. 
  Little is known about the role of hypomethylation in the 
initiation and development of melanoma. In melanoma, a 
group of cancer-testis antigens (CTAs) and several other 
genes have been identified to be aberrantly hypomethylated 
[30-32]. Expression of these genes is repressed in normal 
human skin melanocytes, primarily due to heavily methy-
lated promoter regions in a cell lineage-specific manner. 
Conversely, these same genes can exist in a demethylated 
state and are aberrantly re-expressed in subsets of melanoma 
cells. Current evidence would suggest that reactivation of 
these genes may contribute to overall tumorigenesis. It is 
clear that the expression of these tumor antigens can result in 
their recognition and possible destruction by the host im-
mune system, with the products influencing a range of cellu-
lar processes including cell signaling, transcription, transla-
tion, and chromosomal recombination. Testis-specific pro-
tein Y-encoded (TSPY) is a repeated gene mapped to the 
critical region harboring the gonadoblastoma locus on the Y 
chromosome (GBY); the only oncogenic locus on this male-
specific chromosome and TSPY is considered a putative 
oncogene [29]. 
  DNA-binding histones are directly modified to affect the 
strength with which they bind and subsequently segregate 
DNA from transcriptional machinery. The acetylation of 
lysine residues on histones is associated with transcription-
ally active DNA where deacetylation is associated with 
tightly bound inactive DNA. Additionally, promoter methy-
lation can affect histone activity through the stepwise re-
cruitment of other transcriptional modulators to the methyla-
tion site, as histone acetylation similarly affects promoter 
methylation levels. Each of these processes provides a means 
of controlling gene expression for the maintenance of cell 
homeostasis and has been shown deregulated in many cancer 
types [29]. The enzymes responsible for acetylating and 
deacetylating lysine are histone acetyltransferases (HATs) 
and histone deacetylases (HDACs), respectively. In this 
manner, chromatin can switch between being open (euchro-
matin) or closed (heterochromatin) to transcriptional activity. 
A group of HATs named MYST for family members of K 
(lysine) acetyltransferase 8 (MOZ, Ybf2-Sas3, Sas2) and 
K(lysine) acetyltransferase 5 (Tip60) also includes K(lysine) 
acetyltransferase 7 (HBO1), MOF (also known as MYST 1), 
and monocytic leukemia zinc finger (also known as MYST 
histone acetyltransferase (monocytic leukemia) 3 (MORF) or 
(MOZ-related factor) have a characteristic highly conserved 
370 bp MYST domain with acetyl-CoA binding site and 
function in numerous nuclear processes including transcrip-
tional activation and DNA repair [29]. Interestingly, MYST 
members Tip60 and HBO1 are present in a complex with the 
putative melanoma tumor suppressors inhibitor of growth 
family, member 3/4 (ING3/ 4), respectively [33, 34]. Addi-
tionally, both Tip60 and HBO1 functionally link the nuclear 
factor of kappa light polypeptide gene enhancer in B-cells 1 
(NF-B), while acetylation by Tip60, K(lysine) acetyltrans-
ferase 2A (GCN5), and P300/CBP-associated factor (also 
known as K (lysine) acetyltransferase 2B (PCAF) can stabi-
lize the transcription factor c-Myc, each of which are puta-
tive melanoma oncoproteins [35]. The other groups of 
HATs, E1A binding protein p300 /CREB-binding protein 
(p300/CBP) (that groups adenoviral E1A-associated protein, 
300 kDa and CREB-binding protein and are involved in 
cellular proliferation, differentiation, and apoptosis), have 
been shown to associate with microphthalmia-associated 
transcription factor (MITF), a melanocyte lineage survival 
oncogene [36] that transcriptionally regulates melanoma 
invasiveness, proliferation, and apoptosis [37], is mostly 
upregulated in metastatic melanomas [38] and is associated 
with decreased survival in metastatic melanoma patients 
[39]. In the complex malignant transformation process of 
melanoma, gene expression profiles reveal a loss of expres-
sion of genes that act to counter tumor cell formation includ-
ing cell cycle regulators and proapoptotic genes [40]. Many 
of these tumor supressor genes (TSGs) are shown to be 
downregulated jointly through promoter hypermethylation 
and the reversible deacetylation of lysine residues by 
HDACs of local histones [41]. Furthermore, HDACs are 
known to act on proteins that regulate cellular differentiation, 
proliferation, gene expression, and death; that is, the reason 
why HDAC inhibitors are currently being studied as treat-
ment against the development of malignant melanoma [30]. 
  A new area of recent progress is the study of micro-RNA 
(miR) as factors that mediate in gene expression regulation 
of potential biomarkers in melanoma. Micro-RNA-200 
(miR-200) and miR-205 are both highly expressed in normal 64    The Open Biochemistry Journal, 2011, Volume 5  Rodríguez-Cerdeira and Molares-Vila 
skin and have been shown to specifically target the mRNA 
of the transcriptional repressor of E-Cadherin, zinc finger E-
box binding homeobox 1/2 (ZEB1/2). Thus, they promote 
the expression of E-Cadherin. Consequently, downregulation 
of the miR-200 family and miR-205 leads to the inhibition of 
E-Cadherin, promoting an epithelial-mesenchymal transition 
[42]. Consistent with these studies, miR-205 is often signifi-
cantly downregulated in human epithelial tumors when com-
pared with normal tissues [43]. However, in other profiling 
studies in human epithelial cancer, the miR-200 family 
and/or miR-205 were found upregulated [44]. These appar-
ently contrasting results suggest that miRNAs may have 
different functions in different cells in which the local 
mRNA content may be an important determinant for their 
functions. Future studies are required to dissect the molecu-
lar circuit that underlies these observations. 
  Recent studies have begun to show miRNA expression 
and functions in the development and progression of mela-
noma [45]. Interestingly, the members of the Let-7 family 
were implicated in the suppression of melanoma develop-
ment [46, 47], reminiscent of their functions in other human 
cancers. Given their critical functions in cancers and other 
human diseases, it is conceivable that miRNAs possess great 
potential as therapeutical targets as well in melanoma. Ow-
ing to their small size (~19–24 nucleotides), short oligonu-
cleotides complementary to miRNA sequences, for example, 
antagomir, can effectively block their functions in animals, 
whereas miRNA mimics can enhance miRNA functions 
[42]. 
PROTEOMICS 
  An innovative approach to identify new and better sero-
logical biomarkers in melanoma is the serum proteomic 
profiling. This methodology offers the possibility to screen 
the whole serum proteome for markers that match different 
criteria such as prognostic significance and prediction of 
therapy response. 
  The first promising results showed that patients with 
stage I and stage IV disease can be differentiated by their 
serum proteomic profiles. In this study of serum samples 
from patients with stage I or IV melanoma analyzed by ma-
trix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-ToF) utilizing protein chip technol-
ogy and artificial neural networks (ANNs) correctly identi-
fied the disease stage in 84 of 96 (88%) samples. Forty-four 
of 55 (80%) stage III serum samples were correctly assigned 
as progressors or non-progressors using random sample 
cross-validation statistical methodologies. Twenty-three of 
28 (82%) stage III progressors were correctly identified by 
MALDI-ToF combined with ANN, whereas only 6 of 28 
could be detected by using the S100B marker [48]. 
  Another recent study using proteomic profiling in larger 
sets of sera succeeded in the identification of serum amyloid 
A (SAA) as a new prognostic serum biomarker in melanoma. 
Using an immunonephelometric assay, low serum levels of 
SAA showed a favorable survival compared with patients 
with high serum levels of this protein. By associating a sec-
ond proinflammatory protein, C-reactive protein, to the dos-
age of SAA, it was showed that both proteins have higher 
sensitivity and specificity to predict progression-free as well 
as overall survival than the current standard serum marker, 
S100B [49]. 
  One of the key elements for biomarker discovery will be 
the assays for the identification of low-abundance serum 
proteins. Pre-processing steps have been devised including 
depletion columns for removal of albumin and other major 
proteins, molecular weight cut-off cartridges, acetone pre-
cipitation, gel filtration, ion-exchange chromatography, 
isoelectric focusing, and electrophoresis. More recently, 
multidimensional separation techniques were developed for 
low-abundance protein identification [50]. Coupled with 
tandem mass spectrometry (MS), these approaches allow 
high-throughput protein identification. Owing to its good 
compatibility with online MS detection, nano-liquid chroma-
tography is typically used to separate peptides in shotgun 
proteomics. Even if analytical challenges remain in trying to 
resolve the problems of complexity and dynamic range, 
serum proteomic analysis using multidimensional liquid 
chromatography and MS for shotgun proteomic analysis will 
have an important role in serum clinical biomarker discovery 
[28, 51]. 
CONCLUSIONS 
  With the implementation of new “omics” technologies 
(genomics, epigenetics, and proteomics) in the biomarkers 
discovery area, a wide range of possibilities have opened for 
the uncovering of specific targets of melanoma disease and 
the development of new potential drugs that could improve 
the survival rate and quality of life in patients with malignant 
melanoma. To date, many efforts are being employed in 
multidisciplinary groups for establishing better diagnosis and 
prognosis of the disease. Furthermore, most recent clinical 
trials are testing the laboratory outcomes emerging from the 
application of “omics” platforms. It is a challenging field of 
rapid acquisition of evidence-based knowledge that promises 
an optimistic future for solving the main problems of the 
clinical management of cutaneous melanoma. 
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